缩宫素(Oxytocin) - 药物靶点：OXTR_在研适应症：宫缩乏力，子宫出血，流产_专利_临床

概要

基本信息

简介催产素是一种以商品名OXYTOCIN®销售的OXTR激动剂，是一种因其在妇产科领域的临床疗效而受到称赞的药物。催产素由诺华公司制造，诺华是一家在药物创新方面享有盛誉的制药公司，它于1980年首次在美国获得批准。该药物主要用于产前和产后护理，因为它已被证明可以有效诱导或加强子宫收缩。它的重组激素性质使其成为全球妇产科医生的首选药物，他们为需要产前和产后护理的女性寻求可靠和值得信赖的选择。此外，已发现催产素是孕妇常用的处方药，可帮助她们分娩和分娩或控制产后出血。

药物类型

合成多肽

别名

Oxytocin (JP17/USP/INN)、Oxytocin Nasal Spray、催产素

+ [14]

靶点

OXTR

作用方式

激动剂

作用机制

OXTR激动剂(催产素受体激动剂)

治疗领域

泌尿生殖系统疾病其他疾病神经系统疾病+ [2]

在研适应症

宫缩乏力子宫出血流产+ [12]

非在研适应症

萎缩性阴道炎萎缩注意缺陷障碍伴多动+ [7]

原研机构

Par Sterile Products LLC

在研机构

Tonix Pharmaceuticals, Inc.Viatris Pty Ltd.

ASKA Pharmaceutical Co., Ltd.

+ [3]

非在研机构

Peptonic Medical AB

Trigemina, Inc.Optinose AS

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1980-11-19),

流产出血催产+ [1]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、罕见儿科疾病 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C43H66N12O12S2

InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N

CAS号50-56-6

Sequence Code 124252

来源: *****

关联

860

项与缩宫素相关的临床试验

NCT06364228

/ Not yet recruiting临床2期IIT

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

The overall aim of this study is to determine the efficacy and safety of intranasal oxytocin (OXT) to improve the quality of life and reduce chronic stress levels in the caregivers to the persons with dementia. Randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin (12 or 24 IU) will be conducted by daily administration (once a day) for 21 days (3 weeks).

开始日期2025-05-01

申办/合作机构

University of Nebraska

NCT06808516

/ Not yet recruiting临床2期

The OxyPLEASURE Study - Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - a Double-blind Randomized Placebo-controlled Crossover Trial

The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.

开始日期2025-04-01

申办/合作机构-

NCT06930391

/ RecruitingN/AIIT

Effect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium: An Ex-Vivo Study

Postpartum hemorrhage (PPH) continues to be an increasing problem globally. Uterotonics play an essential role in the pharmacological management of uterine atony. Carbetocin, a long acting analog of oxytocin has been recommended as a first line uterotonic for PPH prophylaxis at cesarean delivery. Considering many woman have associated comorbidities and are at high risk of PPH, finding alternative pharmacological agents is essential. Calcium is a key factor for myometrial contractions and calcium blood levels can be low at the end of pregnancy. Both hypocalcemia and hypercalcemia could lead to a decrease in myometrial contractions. It is already been demonstrated that in both desensitized and naïve myometrium, normocalcemia provides a better uterine tone compared to hypo and hypercalcemia when oxytocin is given as the first uterotonic drug.
Currently, the role of extracelullar calcium in carbetocin- induced contractility is unknown. This will be the first ex vivo study to test the effects of extracellular calcium on oxytocin pretreated and naive myometrium. The results of this study will provide evidence on the use of this safe drug in clinical practice, particularly in women with labour arrest, and provide alternative pharmacological strategies to both prevention and treatment of PPH, thus improving our clinical practice.
The investigators hypothesize that extracellular normocalcemia would provide superior carbetocin-mediated contractility in both naive and oxytocin-pretreated myometrium compared with hypercalcemia and hypocalcemia.

开始日期2025-04-01

申办/合作机构

Samuel Lunenfeld Research Institute

100 项与缩宫素相关的临床结果

登录后查看更多信息

100 项与缩宫素相关的转化医学

登录后查看更多信息

100 项与缩宫素相关的专利（医药）

登录后查看更多信息

29,281

项与缩宫素相关的文献（医药）

2025-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Nomogram for predicting the efficacy of high-intensity focused ultrasound ablation for uterine fibroids based on oxytocin experimentation and ultrasonographic features: a retrospective single-center study

Article

作者: Chen, Sheng ; Chen, Mengqi ; Zhang, Danling ; Wu, Songsong ; Zou, Jianzhong ; Ding, Guisheng

OBJECTIVE:

To develop and validate a nomogram for predicting the effectiveness of high-intensity focused ultrasound (HIFU) ablation for uterine fibroids based on oxytocin experiments combined with sonographic features.

METHODS:

Sixty patients with uterine fibroids treated with HIFU combined with oxytocin for uterine fibroids were retrospectively analyzed. Before HIFU treatment, all patients underwent abdominal ultrasonography and oxytocin testing for classification. Predictive factors were selected through univariate and multivariate logistic regression analyses. A predictive model for the clinical efficacy of HIFU treatment of uterine fibroids was established using the R language. The model was visualized by a nomogram, and its discriminative ability, calibration, and clinical value were evaluated.

RESULTS:

Types of myomas, classification of blood flow around the myomas, location of the myomas, and classification of oxytocin were selected as the final predictive factors to construct the model. The calibration curve of the nomogram demonstrated good consistency between actual observations and nomogram predictions, with an absolute error of 0.066. The model's discriminative ability was evaluated by the area under the curve, which was 0.887 (95% CI: 0.818-0.955). The sensitivity and specificity were 84.4% and 78.8%, respectively, indicating that the model had a good predictive value for the ablation situation. Decision curve analysis showed that the model had high clinical applicability, with the maximum net benefit threshold probability interval ranging from 12.0% to 80.5%.

CONCLUSION:

The prediction model for HIFU treatment of uterine fibroids, based on ultrasound characteristics and oxytocin test, shows strong predictive ability and may help clinicians choose suitable patients for treatment.

2025-07-01·DOMESTIC ANIMAL ENDOCRINOLOGY

Exploring the relationship between plasma and salivary levels of oxytocin, vasopressin, and cortisol in beagles: A preliminary study

Article

作者: Yoon, Minjung ; Jung, Youngwook ; Yang, Kayoung

Oxytocin, vasopressin, and cortisol are widely used as biomarkers to assess the temperament or emotional state of dogs. Typically, these levels are measured in blood; however, this invasive procedure can induce acute pain and stress. Considering the welfare of dogs, it is necessary to replace these procedures with noninvasive methods. Saliva sampling has emerged as a promising, noninvasive alternative for measuring hormonal levels. Nonetheless, it remains unclear whether saliva samples accurately reflect plasma hormonal levels in dogs. The objective of this study was to evaluate the correlations of oxytocin, vasopressin, and cortisol levels between plasma and saliva samples. We simultaneously collected blood and saliva samples from fifteen beagles, aged six, including eleven females and four sterilized males. Due to the limited availability of saliva samples, each analysis was performed on 5-11 dogs. Hormonal levels were quantified using commercial ELISA kits. Linear regression analysis and Pearson's correlation coefficient were used for statistical analysis. Our findings revealed no significant correlation between oxytocin or vasopressin levels in the plasma and salivary samples. However, a significant positive correlation was observed between cortisol levels in plasma and saliva samples. Additionally, oxytocin and vasopressin levels were positively correlated in both plasma and saliva samples. A positive correlation was found between the plasma cortisol and oxytocin levels, whereas no correlation was observed between the salivary cortisol and oxytocin levels. This study provides a foundation for understanding hormonal relationships across different matrices, contributing to the development of alternative sampling methods that prioritize animal welfare.

2025-07-01·NEUROPHARMACOLOGY

Neuronal and therapeutic perspectives on empathic pain: A rational insight

Review

作者: Kujur, Punit Prasanna ; Ellappan, Surendar ; Mondal, Amal Chandra

Empathy is the capacity to experience and understand the feelings of others, thereby playing a key role in a person's mental well-being essentially by promoting kindness and a sense of belongingness to the group. However, too much empathy may result in psychological problems such as empathic distress, compassion fatigue, and burnout, collectively termed empathic pain. Several brain regions are implicated in processing empathic pain perception. Neuroimaging investigations bring in the context of brain structures involved in this emotional exchange, pointing toward the anterior insula (AI) and anterior cingulate cortex (ACC), indicating an overlap between the neural representation of direct and simulative pain. To discern such overlaps, therapeutic techniques for managing empathic pain require understanding different brain regions and their respective neural networks. At the moment, empathic pain is being treated using various methods, including pharmacological treatments such as antidepressants and psychological treatments such as mindfulness or meditation. For instance, researchers have been exploring the modulatory effects of neurotransmitters like serotonin, norepinephrine, and oxytocin on individuals' responses to empathic pain experience. Importantly, this review focuses on the specific brain parts and their unique roles in neurobiological pathways associated with emphatic pain and how shared neural networks play into available treatment options, suggesting possible future health benefits. Such an understanding of empathy can lead to more efficient management of types of care, focusing on enhancing social connections and mental well-being.

315

项与缩宫素相关的新闻（医药）

2025-02-10

·GlobeNewswire-Health Care

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

The Acquired Portfolio of Infectious Disease Assets Includes a Class of Potential Broad Spectrum Oral Antiviral Agents, TNX-3900 with a Host-Directed Mechanism Tonix Plans to Develop the TNX-3900 Series of Molecules as Oral Antivirals Either as Monotherapy or in Combination with Other Antivirals The TNX-3900 Class of Antivirals Has a Novel Mechanism of Action Based on Inhibition of Certain Cathepsin Proteases which are Required for Cell Infection by Many Viruses like SARS-CoV-2 Sina Bavari, Ph.D., Tonix EVP of Infectious Disease R&D and Director of the Frederick, MD Research and Development Center (RDC) was a Scientific Founder of Healion Bio, Inc. Feb. 02, 2023 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets. Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2. “We are excited to develop Healion’s drug programs that include TNX-3900, which is a class of drugs with potential broad spectrum anti-viral activity, either as monotherapies or in combination with other antivirals”, said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Broad-spectrum antiviral agents have the potential to reduce viral load and allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Examples of other classes of host-directed antivirals that have been approved by the U.S. Food and Drug Administration (FDA) include alpha interferon like Pegasys® (peginterferon alfa-2a) for viral hepatitis, the CCR5 antagonist Selzentry® (maraviroc) for HIV, and the anti-IL-6 receptor antagonist monoclonal antibody Actemra® (tocilizumab) for COVID-19.” Sina Bavari, Ph.D., Executive Vice President for Infectious Disease Research at Tonix said, “I am pleased to be reunited with the infectious disease assets of Healion, since I was the scientific founder of Healion after I retired from my position as Chief of R&D at the United States Army Medical Research Institute of Infectious Disease (USAMRIID). While Healion made some progress developing these advanced technologies, Tonix’s state-of-the art facilities and depth of drug development expertise have the potential to advance the TNX-3900 class of drugs into clinical trials. On behalf of the talented scientific team that I direct at our 48,000 square-foot cutting-edge infectious disease research facility in Frederick, Md., I am pleased to add this technology to the therapeutic development programs underway.” TNX-3900 is the term for a series of molecules that inhibit essential cathepsins which are required by viruses such as coronaviruses and filoviruses to infect cells. Because of the unique antiviral mechanism of these compounds, the Company believes they can potentiate the activity of other antivirals with differing mechanisms. The Company believes this makes cathepsin inhibitors suitable for combination therapy. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the second quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second quarter of 2023. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox, TNX-801, a next-generation vaccine to prevent COVID-19, TNX-1850, a platform to make fully human monoclonal antibodies to treat COVID-19, TNX-3600, and humanized anti-SARS-CoV-2 monoclonal antibodies, TNX-3800, recently licensed from Curia. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the second half of 2023. The content above comes from the network. if any infringement, please contact us to modify.

疫苗突破性疗法免疫疗法孤儿药

2025-01-20

·赛柏蓝

原研药：集采影响有多大？

特约作者 | 张自然博士责任编辑 | 郑瑶近日，原研药和集采引起广泛热议。集采对原研药影响有多大？原研药在集采中表现如何？ 01 涉及品种数以前5批及第10批国采为例，涉及原研药≥2个的有16家外企。其中，涉及原研药数量最多的是辉瑞、阿斯利康，分别涉及27个和20个原研药。辉瑞连续十多年雄踞外企在华销售榜首，近三年被阿斯利康取代冠军宝座，所以，国采涉及这两家的原研药数量最多也就不足为奇了；其次是默沙东、诺华、勃林格殷格翰、葛兰素、拜耳和赛诺菲等6家知名外企，国采涉及原研药都超过10个，分别有15个、14个、13个、13个、12个和10个；礼来、强生和施贵宝都涉及8个原研药；日本的武田、第一三共和中外制药分别涉及5个、4个和2个原研药。 02 中选品种数国采已进行了10批，除第10批外，每批都有原研药中选。前十批国采，共22家外企有原研药中选。其中，中选原研药数量最多的是赛诺菲，共中选了4个，如波立维（硫酸氢氯吡格雷片）、安博诺（厄贝沙坦氢氯噻嗪片）、索里昂（氨磺必利片）、注射用奥沙利铂。中选2个原研药的外企有6家，即拜耳、德国贝朗医疗、勃林格殷格翰、辉瑞、默沙东和通用电气药业。如拜耳的拜糖平（阿卡波糖）、贝朗的ω-3鱼油中/长链脂肪乳注射液、勃林格殷格翰的优尼（美洛昔康片）、辉瑞的斯沃（利奈唑胺片）、默沙东的顺尔宁（孟鲁司特钠片）以及通用电气的碘海醇注射液等。其他如阿斯利康、费森尤斯、葛兰素、施贵宝等15家外企都各中选了1个原研药。 03 降幅因原研药还要叠加专利悬崖效应，一般要以较大的降价幅度才能中选。但也不尽然，也有降幅很小就中选的。在前十批国采中选的原研药中，降价幅度最小的是丹麦利奥（LEO）的依安凡。降幅＜40%的有2个原研药，即丹麦利奥（LEO）的依安凡（阿法骨化醇软胶囊）、博莱科的典比乐（碘帕醇注射液），分别只降了30%、32%即一举中选；降幅40～60%的有6个原研药，即意大利ALFASIGMA S.p.A.的左卡尼汀注射液49%、德国贝朗医疗的中/长链脂肪乳注射液C8~24Ve50%和ω-3鱼油中/长链脂肪乳注射液60%、默沙东的顺尔宁（孟鲁司特钠）54%和瑞美隆（米氮平片）57%、葛兰素的安福达（度他雄胺软胶囊）55%、礼来的力比泰（培美曲塞）60%；降幅60～70%的有4个原研药，即通用电气的欧乃派克（碘海醇注射液）61%、费森尤斯卡比的敏新（脂肪乳氨基酸17葡萄糖）66%、施贵宝的蒙诺（福辛普利钠）69%、辉凌的巧特欣（卡贝缩宫素注射剂）70%。 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

带量采购核酸药物

2025-01-07

·GlobeNewswire-Health Care

Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences

CHATHAM, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix management will present and host investor meetings at the following January investor conferences: 8th Annual Neuroscience Innovation Forum by Sachs Associates Company PresentationPresenter:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate:Sunday, January 12, 2025Place:Marines Memorial Club, San Francisco, Calif.Time:11:15 a.m. PTRoom:Track A – Room Rosenberg PanelParticipant:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsTitle:Revolutionizing Neuropsychiatric Treatments: Novel Approaches PanelDate:Sunday, January 12, 2025Place:Marines Memorial Club, San Francisco, Calif.Time:1:15 p.m. PT 2025 Biotech ShowcasePresenter:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate:Tuesday, January 14, 2025Place:Hilton San Francisco Union Square, San Francisco, Calif.Time:10:00 a.m. PTRoom:Yosemite C (Ballroom level) Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators. Replays of both webcasts of the Company’s presentations at the Neuroscience Innovation Forum and the 2025 Biotech Showcase will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following each presentation. Tonix Pharmaceuticals Holding Corp.* Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing approval. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@icrhealthcare.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432

临床3期快速通道临床2期疫苗

100 项与缩宫素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00089	缩宫素	H01BB02	DB00107

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
宫缩乏力	澳大利亚	Viatris Pty Ltd.	1991-08-21
子宫出血	日本	ASKA Pharmaceutical Co., Ltd.	1984-07-12
流产	美国	Endo Operations Ltd.	1980-11-19
出血	美国	Endo Operations Ltd.	1980-11-19
催产	美国	Endo Operations Ltd.	1980-11-19
产后出血	美国	Endo Operations Ltd.	1980-11-19
人工流产	-	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
自闭症谱系障碍	临床3期	美国	The General Hospital Corp.	2017-10-09
心房中隔缺损	临床3期	美国	The General Hospital Corp.	2017-10-09
术后疼痛	临床2期	-	The Brigham & Women's Hospital, Inc.	2024-07-01
社交恐怖症	临床2期	美国	Tonix Pharmaceuticals, Inc.	2023-07-17
儿童肥胖	临床2期	美国	Tonix Pharmaceuticals, Inc.	2023-07-10
先兆偏头痛	临床2期	美国	Tonix Pharmaceuticals, Inc.	2022-12-06
无先兆偏头痛	临床2期	美国	Tonix Pharmaceuticals, Inc.	2022-12-06
肥胖	临床2期	美国	The General Hospital Corp.	2017-07-01
躯体变形障碍	临床2期	美国	The General Hospital Corp.	2014-12-01
短指D型	临床2期	美国	The General Hospital Corp.	2014-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05679908 (PREVENTION, CTgov)	临床2期	先兆偏头痛 \| 无先兆偏头痛	88	Placebo Nasal Spray (Placebo)	顧鬱衊壓憲鏇選鹽餘範(製構獵獵選糧壓夢觸遞) = 獵夢鑰廠憲觸艱衊齋繭艱網範鬱顧夢遞鏇夢構 (鏇築簾繭襯選淵獵醖憲, 1.366) 更多	-	2025-02-25
				Placebo Nasal Spray+TNX-1900 (TNX-1900 Low Dose)	顧鬱衊壓憲鏇選鹽餘範(製構獵獵選糧壓夢觸遞) = 簾獵製蓋膚鏇憲壓繭積艱網範鬱顧夢遞鏇夢構 (鏇築簾繭襯選淵獵醖憲, 1.246) 更多
NCT02505984 (IN-OXT, CTgov)	临床2期	产后抑郁症 \| 创伤后应激障碍 \| 焦虑症	56	Oxytocin (Oxytocin)	餘襯網衊製鹹蓋積簾窪(鏇齋膚鬱廠蓋積構壓鹹) = 衊鏇鹹簾襯網艱餘遞鬱蓋繭醖鑰餘築淵膚鹹築 (餘齋膚網膚蓋積鏇夢憲, 6.15) 更多	-	2025-02-25
				Placebo (Placebo)	餘襯網衊製鹹蓋積簾窪(鏇齋膚鬱廠蓋積構壓鹹) = 觸積齋範鹽選繭繭願窪蓋繭醖鑰餘築淵膚鹹築 (餘齋膚網膚蓋積鏇夢憲, 6.92) 更多
NCT03197662 (CTgov)	临床2期	多食症 \| 普拉德-威利综合症	32	Oxytocin (Experimental: Intranasal Oxytocin (IN-OXT))	製膚艱鏇衊醖夢膚窪願(廠獵構範範襯構膚簾齋) = 鏇廠觸齋願鬱積齋鬱淵製鏇廠廠淵網鹽餘製艱 (鏇淵膚鑰餘遞製壓範獵, 5.65) 更多	-	2025-02-07
				Matched Placebo (Placebo Comparator: Matched Placebo)	製膚艱鏇衊醖夢膚窪願(廠獵構範範襯構膚簾齋) = 鹹積淵鑰簾憲餘網繭觸製鏇廠廠淵網鹽餘製艱 (鏇淵膚鑰餘遞製壓範獵, 5.05) 更多
NCT02737436 (OT-MOM, CTgov)	N/A	-	132	Placebo (Placebo)	願獵簾醖觸範淵鏇窪憲(製繭積鏇窪鑰窪鹽顧鹽) = 願淵憲襯餘製觸顧遞窪窪鑰繭廠窪築觸窪衊築 (繭糧築糧蓋選壓簾範壓, 鬱糧壓構鹽齋觸蓋製積 ~ 夢淵範網構簾醖餘衊觸) 更多	-	2025-01-28
				Functional MRI scanning+Intranasal Oxytocin (Oxytocin)	願獵簾醖觸範淵鏇窪憲(製繭積鏇窪鑰窪鹽顧鹽) = 衊遞艱製襯鏇鹽蓋壓廠窪鑰繭廠窪築觸窪衊築 (繭糧築糧蓋選壓簾範壓, 簾選構鹹齋廠構願蓋艱 ~ 蓋糧廠鑰鏇積簾壓醖淵) 更多
NCT04902729 (Pubmed \| Can J Anaesth)	N/A	-	-	Oxytocin 1 IU iv	衊齋淵繭選醖衊願鏇鏇(願窪襯膚構獵憲淵襯築) = 齋顧鑰選鹽餘鏇築鹹糧鹽鬱襯範選艱襯齋餘窪 (廠齋淵淵艱築齋淵廠構, 7 ~ 8)	积极	2025-01-06
				Carbetocin 80 µg iv	衊齋淵繭選醖衊願鏇鏇(願窪襯膚構獵憲淵襯築) = 製選製構選範構餘廠選鹽鬱襯範選艱襯齋餘窪 (廠齋淵淵艱築齋淵廠構, 8 ~ 9)
NCT04946006 (Pubmed \| Can J Anaesth)	N/A	维持	40	Oxytocin maintenance infusion 4.5 IU/hr	顧鏇繭鬱鹽糧製糧醖餘(製網廠鏇壓鬱淵範顧鏇) = 窪膚壓衊遞襯願鏇網積衊繭顧鑰獵襯糧鹹艱鏇 (膚獵築夢夢顧襯餘網鹽 ) 更多	积极	2024-09-19
NCT05672667 (CTgov)	临床1期	-	25	intravenous oxytocin	願鬱齋觸醖製憲鏇廠夢(積獵簾糧鹽廠網選鏇顧) = 範鹽積積鹽鹽鹽窪壓艱鹽齋窪鹽積繭選積構範 (獵觸鹹壓艱鹹餘醖糧願, 47) 更多	-	2024-08-06
Randomized Controlled Trial of Intranasal Oxytocin for the Treatment of Obesity (ENDO2024)	N/A	肥胖	-	Intranasal Oxytocin (24 IU)	膚願鹹築積築網遞獵鹽(製齋鹹選壓壓鹹鬱製鬱) = 憲製夢憲鹽製簾鬱鏇繭壓範蓋醖壓獵選築構網 (積繭壓鹽鹽構壓鏇襯餘 ) 更多	不佳	2024-06-01
				Placebo	膚願鹹築積築網遞獵鹽(製齋鹹選壓壓鹹鬱製鬱) = 鏇憲積夢鏇範壓齋淵選壓範蓋醖壓獵選築構網 (積繭壓鹽鹽構壓鏇襯餘 ) 更多
NCT03043053 (Eight Weeks Intranasal Oxytocin vs. Placebo, ENDO2024)	临床2期	肥胖 Oxytocin \| Arginine-Vasopressin	61	Intranasal Oxytocin (24 IU)	鹹獵淵選壓醖獵簾鏇鏇(衊鏇範範膚築窪鬱艱築) = 窪製糧憲簾鏇糧蓋遞鑰鑰範憲憲餘膚襯窪顧襯 (襯鬱壓觸淵夢觸餘糧鏇, -2.81 ~ 4.01) 更多	不佳	2024-06-01
NCT03593473 (CTgov)	临床2期	产后抑郁症 \| 心理压力 \| 焦虑症	109	Intranasal Oxytocin (Intranasal Oxytocin)	襯鑰憲繭齋鹽衊衊鑰築(廠觸簾遞襯遞範觸鑰鹹) = 簾鹽獵鬱鹽願淵廠網衊鹹鹹餘網積憲餘壓構鑰 (網鬱獵艱憲範壓餘顧積, 13.46) 更多	-	2024-05-24
				Placebo (Placebo)	襯鑰憲繭齋鹽衊衊鑰築(廠觸簾遞襯遞範觸鑰鹹) = 鬱壓衊觸鹹鹹構製夢遞鹹鹹餘網積憲餘壓構鑰 (網鬱獵艱憲範壓餘顧積, 10.84) 更多